Multicenter cooperative observational study of idiopathic pulmonary fibrosis with non-small cell lung cancer

• 作者: Isamu Okamoto Kazunobu Itoh Kentaro Watanabe Nobutaka Edakuni Noriyuki Ebi Shinichiro Hayashi Shinji Fujii Shoji Tokunaga Takashige Maeyama Yoichi Nakanishi
• 来源期刊: 世界呼吸病学杂志
• 学科: 医学
• 关键词: NON-SMALL cell lung cancer CHEMOTHERAPY IDIOPATHIC pulmonary FIBROSIS Acute EXACERBATION Best supportive care
• 年，卷（期）: 2016,（1）
• 页码范围: 42-48
• 页数: 7页
• 分类号: R

摘要

AIM:To research the natural course of idiopathic pulmonary fibrosis(IPF)with advanced non-small cell lung cancer(NSCLC)and the association between acute exacerbation(AE)of IPF and chemotherapy(CT).METHODS:From May 2007 through April 2011,17 CT naive patients with IPF and advanced NSCLC were enrolled.Patients were classified into best supportive care(BSC)group or CT group based on the patient’s preference.Patients in the CT group received carboplatin(CBDCA)(AUC 5-6)plus paclitaxel(PTX)(175-200 mg/m2)on day 1 of each 21-d cycle as first-line therapy.RESULTS:All patients but one chose the CT group.In the CT group,the objective response rate was 38%.The most frequent toxicity≥grade 3 was neutropenia(88%).Two patients(12.5%)developed AE-IPF.The median progression-free survival,the median survival time and the 1-year survival rate were 4.1 mo,8.7 mo and 35%,respectively.Second-line CT-related AE and CT-unrelated AE occurred in 2 and 3 patients(1:BSC group;2:CT group),respectively.Seven(41%)of all patients developed AE-IPF throughout the clinical course,and 6 of 7 patients with AE-IPF died within one month.CONCLUSION:The incidence of AE-IPF was higher among IPF patients with advanced NSCLC than among those without NSCLC.CBDCA plus PTX regimen was tolerable and effective.However,AE-IPF has a fatal toxicity with or without CT in IPF patients with advanced NSCLC.